

**RECEIVED
CENTRAL FAX CENTER**

NOV 05 2004

Attorney Docket No.: 6176.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Persson et al.

Application No.: 09/848,107

Group Art Unit: 1653

Filed: May 3, 2001

Examiner: S. Snedden

For: Human Coagulation Factor VII Variants

TERMINAL DISCLAIMER UNDER 37 CFR 1.321

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I am an attorney of record for the instant application.

Novo Nordisk A/S is the assignee of the entire interest in the above-identified application (assignment from the named inventors to Novo Nordisk A/S was recorded on Reel 012092 and Frame 0894.

The terminal part of the statutory term of any patent granted on the above-identified application, which would extend beyond the expiration date of the full statutory term of

any patent granted on application no. 10/109,498
is hereby disclaimed, except as provided below, and it is agreed that any patent so granted on the above-identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to

any patent granted on application no. 09/848,107
this agreement to run with any patent granted on the above-identified application and to be binding upon the grantee, its successors and assigns.

In making the above disclaimer, disclaimant does not disclaim the terminal part of any patent granted on the above-identified application that would extend beyond the expiration date of the full statutory term of


any patent granted on application no. 10/109,498

in the event that the latter later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued in any matter or is terminated prior to expiration of its full statutory term as presently shortened by any terminal disclaimer, except for the separation of legal title stated above.

Please charge the required fee, estimated to be \$110.00, to Novo Nordisk of North America, Inc. Deposit Account No. 14-1447. Please credit any overpayment to Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Date: November 5, 2004

Respectfully submitted,


Reza Green, Reg. No. 38,475
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

Use the following customer number for all correspondence regarding this application.

23650

PATENT TRADEMARK OFFICE

**RECEIVED
CENTRAL FAX CENTER**

NOV 05 2004

Attorney Docket No.: 6176.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Persson et al.

Application No.: 09/848,107

Group Art Unit: 1653

Filed: May 3, 2001

Examiner: S. Snedden

For: Human Coagulation Factor VII Variants

TERMINAL DISCLAIMER UNDER 37 CFR 1.321Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I am an attorney of record for the instant application.

Novo Nordisk A/S is the assignee of the entire interest in the above-identified application (assignment from the named inventors to Novo Nordisk A/S was recorded on Reel 012092 and Frame 0894.

The terminal part of the statutory term of any patent granted on the above-identified application, which would extend beyond the expiration date of the full statutory term of

any patent granted on application no. 10/109,498

is hereby disclaimed, except as provided below, and it is agreed that any patent so granted on the above-identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to

any patent granted on application no. 09/848,107

this agreement to run with any patent granted on the above-identified application and to be binding upon the grantee, its successors and assigns.

In making the above disclaimer, disclaimant does not disclaim the terminal part of any patent granted on the above-identified application that would extend beyond the expiration date of the full statutory term of


any patent granted on application no. 10/109,498

in the event that the latter later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued in any matter or is terminated prior to expiration of its full statutory term as presently shortened by any terminal disclaimer, except for the separation of legal title stated above.

Please charge the required fee, estimated to be \$110.00, to Novo Nordisk of North America, Inc. Deposit Account No. 14-1447. Please credit any overpayment to Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Date: November 5, 2004

Respectfully submitted,


Reza Green, Reg. No. 38,475
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

Use the following customer number for all correspondence regarding this application.

23650

PATENT TRADEMARK OFFICE

**RECEIVED
CENTRAL FAX CENTER**

NOV 05 2004

PATENT

Attorney Docket No.: 6176.200-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Persson et al.

Application No.: 09/848,107

Group Art Unit: 1653

Filed: May 3, 2001

Examiner: S. Snedden

For: Human Coagulation Factor VII Variants

TERMINAL DISCLAIMER UNDER 37 CFR 1.321Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I am an attorney of record for the instant application.

Novo Nordisk A/S is the assignee of the entire interest in the above-identified application (assignment from the named inventors to Novo Nordisk A/S was recorded on , Reel 012092 Frame 0894.

The terminal part of the statutory term of any patent granted on the above-identified application, which would extend beyond the expiration date of the full statutory term of

any patent granted on application no. 10/281,727

is hereby disclaimed, except as provided below, and it is agreed that any patent so granted on the above-identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to

any patent granted on application no. 09/848,107

this agreement to run with any patent granted on the above-identified application and to be binding upon the grantee, its successors and assigns.

In making the above disclaimer, disclaimant does not disclaim the terminal part of any patent granted on the above-identified application that would extend beyond the expiration date of the full statutory term of

any patent granted on application no. 10/281,727

in the event that the latter later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued in any matter or is terminated prior to expiration of its full statutory term as presently shortened by any terminal disclaimer, except for the separation of legal title stated above.

Please charge the required fee, estimated to be \$110.00, to Novo Nordisk of North America, Inc. Deposit Account No. 14-1447. Please credit any overpayment to Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Date: November 5, 2004

Respectfully submitted,



Reza Green, Reg. No. 38,475
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

Use the following customer number for all correspondence regarding this application.

23650

PATENT TRADEMARK OFFICE

NOV 05 2004

Attorney Docket No.: 6176.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Persson et al.

Application No.: 09/848,107

Group Art Unit: 1653

Filed: May 3, 2001

Examiner: S. Snedden

For: Human Coagulation Factor VII Variants

TERMINAL DISCLAIMER UNDER 37 CFR 1.321

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I am an attorney of record for the instant application.

Novo Nordisk A/S is the assignee of the entire interest in the above-identified application (assignment from the named inventors to Novo Nordisk A/S was recorded on , Reel 012092 Frame 0894.

The terminal part of the statutory term of any patent granted on the above-identified application, which would extend beyond the expiration date of the full statutory term of

any patent granted on application no. 10/281,727

is hereby disclaimed, except as provided below, and it is agreed that any patent so granted on the above-identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to

any patent granted on application no. 09/848,107

this agreement to run with any patent granted on the above-identified application and to be binding upon the grantee, its successors and assigns.

In making the above disclaimer, disclaimant does not disclaim the terminal part of any patent granted on the above-identified application that would extend beyond the expiration date of the full statutory term of


any patent granted on application no. 10/281,727

in the event that the latter later; expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued in any matter or is terminated prior to expiration of its full statutory term as presently shortened by any terminal disclaimer, except for the separation of legal title stated above.

Please charge the required fee, estimated to be \$110.00, to Novo Nordisk of North America, Inc. Deposit Account No. 14-1447. Please credit any overpayment to Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Date: November 5, 2004

Respectfully submitted,


Reza Green, Reg. No. 38,475
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

Use the following customer number for all correspondence regarding this application.

23650

PATENT TRADEMARK OFFICE